MDM2 SNP309 polymorphism is associated with colorectal cancer risk

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Weizhi ^a,b   Du, Mulong ^b,c   Gu, Dongying ^d   Zhu, Lingjun ^a   Chu, Haiyan ^b   Tong, Na ^b   Zhang, Zhengdong ^b,c   Xu, Zekuan ^a   Wang, Meilin ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; PROTEIN P53;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; CELL TRANSFORMATION; COLORECTAL TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; PROMOTER REGION; RISK; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RISK; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84900030400     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04851     Document Type: Article

References (46)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
2. Siegel, R.,Naishadham,D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin 63, 11-30 (2013).
3. Qiong, C., Zhicai, L. & Lanping, C. An Analysis of Incidence and Mortality of Colorectal Cancer in China, 2003,2007. China Cancer 21, 179-182 (2012).
4. Lichtenstein, P. et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland.NEngl J Med 343, 78-85 (2000). (Pubitemid 30451850)
5. Markowitz, S. D. & Bertagnolli, M. M. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361, 2449-2460 (2009).
6. Bargonetti, J. & Manfredi, J. J. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14, 86-91 (2002). (Pubitemid 34072969)
7. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ, 247-270 (2004).
8. Momand, J., Zambetti, G. P., Olson, D. C., George, D. & Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- mediated transactivation. Cell 69, 1237-1245 (1992).
9. Oliner, J. D. et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993). (Pubitemid 23132165)
10. Haupt, Y.,Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997). (Pubitemid 27220766)
11. Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997). (Pubitemid 27220767)
12. Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L. & Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358, 80-83 (1992).
13. Onel, K. & Cordon-Cardo, C. MDM2 and prognosis. Mol Cancer Res 2, 1-8 (2004). (Pubitemid 38167102)
14. Tachibana, M. et al. Dysfunction of p53 pathway in human colorectal cancer: analysis of p53 gene mutation and the expression of the p53-associated factors p14ARF, p33ING1, p21WAF1 and MDM2. Int J Oncol 25, 913-920 (2004).
15. Bond, G. L. et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591-602 (2004). (Pubitemid 39535748)
16. Lind, H., Zienolddiny, S., Ekstrom, P. O., Skaug, V. & Haugen, A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 119, 718-721 (2006). (Pubitemid 43955729)
17. Hong, Y. et al. The role of P53 and MDM2 polymorphisms in the risk of esophageal squamous cell carcinoma. Cancer Res 65, 9582-9587 (2005). (Pubitemid 41508029)
18. Ma, H. et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett 240, 261-267 (2006). (Pubitemid 44093826)
19. Alazzouzi, H. et al. Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. J Med Genet 44, 75-80 (2007). (Pubitemid 46142843)
20. Joshi, A. M. et al. TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn J Clin Oncol 41, 232-238 (2011).
21. Chaar, I. et al. Impact of MDM2 polymorphism: increased risk of developing colorectal cancer and a poor prognosis in the Tunisian population. Eur J Gastroenterol Hepatol 24, 320-327 (2012).
22. Alhopuro, P. et al. The MDM2 promoter polymorphism SNP309T - .G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genet 42, 694-698 (2005). (Pubitemid 41306059)
23. Talseth, B. A. et al. MDM2 SNP309 T.G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer 120, 563-565 (2007). (Pubitemid 44969027)
24. Zhang, Y. et al. Polymorphisms in TP53 and MDM2 contribute to higher risk of colorectal cancer in Chinese population: a hospital-based, case-control study. Mol Biol Rep 39, 9661-9668 (2012).
25. Zhu, L. et al. A Functional Polymorphism in miRNA-196a2 Is Associated with Colorectal Cancer Risk in a Chinese Population. DNA Cell Biol 31, 350-4 (2012).
26. Sotamaa, K. et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11, 6840-6844 (2005). (Pubitemid 41428738)
27. Menin, C. et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. JNatl Cancer Inst 98, 285-288 (2006). (Pubitemid 43264712)
28. Chen, Y. L., Chang, Y. S., Chang, J.G. & Wu, S.M.Genotyping of single nucleotide polymorphism in MDM2 genes by universal fluorescence primer PCR and capillary electrophoresis. Anal Bioanal Chem 394, 1291-1297 (2009).
29. Sugano, N. et al. MDM2 gene amplification in colorectal cancer is associated with disease progression at the primary site, but inversely correlated with distant metastasis. Gene Chromosome Canc 49, 620-629 (2010).
30. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177-188 (1986). (Pubitemid 17189972)
31. Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719-748 (1959).
32. Egger, M., Davey Smith, G., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315, 629-634 (1997). (Pubitemid 27387172)
33. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-1101 (1994).
34. Martin, K. et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375, 691-694 (1995).
35. Xiao, Z. X. et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375, 694-698 (1995).
36. Ries, S. et al. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103, 321-330 (2000).
37. Gudas, J. M. et al.Differential expression of multipleMDM2messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1, 71-80 (1995).
38. Maya, R. et al. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev 15, 1067-1077 (2001). (Pubitemid 32417300)
39. Cao, X., Zhang, T., Zhao, Z. & Zhao, T. MDM2 SNP309 polymorphism and colorectal cancer risk: a meta-analysis. DNA Cell Biol 31, 355-359 (2012).
40. Knappskog, S. et al. The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell 19, 273-282 (2011).
41. zur Hausen, H. Red meat consumption and cancer: reasons to suspect involvement of bovine infectious factors in colorectal cancer. Int J Cancer 130, 2475-2483 (2012).
42. Terry, P., Ekbom, A., Lichtenstein, P., Feychting, M. & Wolk, A. Long-term tobacco smoking and colorectal cancer in a prospective cohort study. Int J Cancer 91, 585-587 (2001). (Pubitemid 32115118)
43. Fedirko, V. et al. Alcohol drinking and colorectal cancer risk: an overall and doseresponse meta-analysis of published studies. Ann Oncol 22, 1958-1972 (2011).
44. Freudenheim, J. L. et al. Diet and alcohol consumption in relation to p53 mutations in breast tumors. Carcinogenesis 25, 931-939 (2004). (Pubitemid 38886079)
45. Bond, G. L. et al. MDM2 SNP309 accelerates colorectal tumour formation in women. J Med Genet 43, 950-952 (2006). (Pubitemid 46080193)
46. Bond, G. L. et al.MDM2SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res 66, 5104-5110 (2006). (Pubitemid 43844932)